Clinical trial · Observational
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC
LncRNA NNT-AS1/Hsa-miR-485-5p/HSP90 Axis In-silico and Clinical Prospect correlated-to Histologic Grades-based CRC Stratification: A Step Toward ncRNA Precision
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current study will compare the blood expression level of lncRNA NNT-AS1 and hsa-miR-485-5p, as well as heat shock protein 90 (HSP90) serum levels in both healthy and CRC Egyptian patients' cohort peripheral blood samples. Second, examine if lncRNA NNT-AS1/hsa-miR-485 5p/HSP90 axis, or individually investigated, would be used as a non-invasive molecular precision biomarker in liquid biopsy for better diagnostic utility for CRC patients. Also, based on CRC patients' group stratification by histologic grades 1-3. Finally, investigate the probable link/correlation between lncRNA NNT-AS1/hsa-miR-485-5p/HSP90 as an axis or individually in CRC Egyptian patients' cohort in relation to demographic data or clinicopathological characteristics. All findings will be confirmed or ruled out by in silico means as well.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Patient group
- description
- A total of 60 CRC pateints' were enrolled in the study. CRC pateints' were treatment-naïve Egyptian patients' cohort admitted to the Clinical Oncology Clinic, National Cancer Institute (NCI), Cairo University, Cairo, Egypt. Male-to-female 1:1 (30/30) and their age range 24-76 years.
- label
- Healthy Control
- description
- 28 age-matched and sex-matched apparently healthy volunteers, randomly selected from subjects enlisted during normal check-up examination or during blood donation. The control group participants were not taking any medication or suffering from any disease. Controls age range is 40-60 years and 13:15 male-to-female.
Primary outcomes (4)
- measure
- determination ofncRNA Expression pattern in CRC patients' in comparison to the control group
- timeFrame
- 9 months
- measure
- determination of HSP90 protein concentration in control and CRC cases
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 24 Years
- Maximum age
- 76 Years
Show eligibility criteria text
Inclusion Criteria: * CRC diagnosed patients that is clinically confirmed by colonoscopy, abdominal radio-imaging, and histopathologicaly. Exclusion Criteria: * individuals receiving chemotherapy, radiation, or undergone surgery * patients with blood disorders * patients with any cancer other than CRC. * Individuals with inadequate data or missing histopathological diagnoses * distant metastases
References
Publications (1)
- RESULTEl-Sheikh NM, Abulsoud AI, Fawzy A, Wasfey EF, Hamdy NM. LncRNA NNT-AS1/hsa-miR-485-5p/HSP90 axis in-silico and clinical prospect correlated-to histologic grades-based CRC stratification: A step toward ncRNA Precision. Pathol Res Pract. 2023 Jul;247:154570. doi: 10.1016/j.prp.2023.154570. Epub 2023 May 24. PMID 37244051